Tirzepatide vs Liraglutide (Saxenda / Victoza)
Tirzepatide (Mounjaro / Zepbound) vs Liraglutide (Saxenda / Victoza): weekly dual GLP-1 + GIP vs first-generation daily GLP-1. The generational gap in effect size.
The verdict
Two generations apart. Tirzepatide hits two receptors (GLP-1 plus GIP), is dosed once weekly, and posts some of the largest weight-loss figures of any approved obesity drug. Liraglutide is the single-receptor daily GLP-1 from a decade earlier, with a much smaller average effect. Both are FDA-approved, so this is not about proof, it is about power and convenience, and Tirzepatide wins both. Liraglutide mainly makes sense when it is the covered option or when someone specifically wants a shorter-acting daily drug.
Tirzepatide is the prescription weight-loss drug sold as Mounjaro (diabetes) or Zepbound (weight loss). It hits two appetite-control receptors at once. Most users lose 15-20% of body weight over several months. One injection per week.
Liraglutide is the daily-injection GLP-1 that came before Semaglutide. Sold as Saxenda for weight loss and Victoza for diabetes. Same family as Wegovy/Ozempic but you inject it every day instead of weekly. Less convenient, but covered by some insurance plans that don't cover the weekly versions.
Which one should you pick?
Pick Tirzepatide if users who couldn't tolerate semaglutide or metabolic-syndrome adults under provider guidance.
Pick Liraglutide (Saxenda / Victoza) if patients on insurance plans that cover saxenda but not wegovy or users who don't tolerate weekly semaglutide titration.
Still torn between Tirzepatide and Liraglutide (Saxenda / Victoza)?
The AI Coach reads both, asks about your goal and experience, and tells you which one actually fits — plus how to dose and stack it. Free.